Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sabra Health Care REIT (SBRA)

Sabra Health Care REIT Q3 net income $0.13 a share; raises 2024 normalized FFO guidance

Positive Impact 4 of 5 guidance Written later

Sabra Health Care REIT reported third-quarter 2024 net income of $29.8 million, or $0.13 per diluted share, compared with a net loss of $15.1 million, or $0.07 per share, a year earlier. Total revenues rose to $178.0 million from $161.6 million. The company raised the low and high ends of its 2024 normalized FFO guidance and raised the midpoint of its normalized AFFO guidance, but lowered the top end of its net income guidance.

Key points

  • Q3 2024 normalized FFO was $0.35 per diluted share, versus $0.33 in Q3 2023; normalized AFFO was $0.37, versus $0.34.
  • 2024 normalized FFO guidance raised to $1.39-$1.40 from $1.36-$1.39; normalized AFFO guidance raised to $1.43-$1.44 from $1.41-$1.44.
  • 2024 net income guidance is $0.48-$0.49, down from the prior top end of $0.51.
  • Board declared a quarterly dividend of $0.30 per share, payable November 29, 2024, to holders of record on November 15, 2024.

The filing

CompanySabra Health Care REIT (SBRA)
Form8-K, current report
Filed with the SECOct 31, 2024, 4:05 PM ET
Accession number0001492298-24-000030

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 31, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.